Alnylam Pharmaceuticals (NASDAQ:ALNY) Given “Buy” Rating at Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a report released on Friday,Benzinga reports. They currently have a $320.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 12.94% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 11th. Scotiabank lowered their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. Chardan Capital restated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Morgan Stanley lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $310.22.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $283.34 on Friday. The firm has a market cap of $36.68 billion, a P/E ratio of -130.57 and a beta of 0.39. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The business’s 50 day moving average price is $257.16 and its 200-day moving average price is $259.69. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares in the last quarter. Park Square Financial Group LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $28,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $33,000. Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, True Wealth Design LLC grew its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.